Anti-VISTA antibodies and fragments, uses thereof, and methods of identifying same

Patent metadata

Field	Value
Publication number	US-12441801-B2
Application number	US-202117325792-A
Country	US
Kind code	B2
Filing date	May 20, 2021
Priority date	Dec 24, 2013
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.

First claim

What is claimed:

1. A nucleic acid encoding an antibody or antigen-binding fragment thereof comprising an antigen binding region that binds to a V-domain Ig Suppressor of T cell Activation (VISTA), wherein the encoded antigen binding region of the antibody or antigen binding region comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and which further comprises an antibody VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO:29 and a VL CDR3 having the amino acid sequence of SEQ ID NO:30.

2. The nucleic acid of claim 1 , wherein the encoded antibody or antigen-binding fragment which binds VISTA comprises a VH domain comprising SEQ ID NO:37 and a VL domain comprising SEQ ID NO:44.

3. The nucleic acid of claim 1 , wherein the encoded antibody or antigen-binding fragment which binds VISTA comprises an antibody heavy chain comprising SEQ ID NO:61 and an antibody light chain comprising SEQ ID NO:56.

4. The nucleic acid of claim 1 , wherein the encoded antibody or antigen-binding fragment enhances T cell activation.

5. A recombinant cell which comprises the nucleic acid of claim 1 .

6. A recombinant cell which comprises the nucleic acid of claim 2 .

7. A recombinant cell which comprises the nucleic acid of claim 3 .

8. A recombinant cell which comprises the nucleic acid of claim 4 .

9. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 5 .

10. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 6 .

11. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 7 .

12. A method of producing the anti-VISTA antibody or antigen binding fragment thereof comprising culturing the recombinant cell of claim 8 .

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Snyder Linda A
• Powers Gordon
• Ubani Enrique Zudaire
• Marvel Douglas Matthew

Classifications

• C07K16/2818

  against CD28 or CD152 · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title